HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NuSkin

This article was originally published in The Rose Sheet

Executive Summary

Entering South American market, with operations commencing in Brazil Nov. 11, the company announced Sept. 22. Nu Skin will launch 28 products into the country, including locally manufactured Scion skin and hair care products. Brazil will serve as a "hub for future expansion throughout South America," Nu Skin said. The direct marketer is also investigating potential expansion into Chile and Argentina. Brazil is the 27th country the firm has entered - Nu Skin expanded into Denmark and Sweden in September ("The Rose Sheet" Aug. 24, In Brief). Brazil "represents a significant growth opportunity," Nu Skin noted, adding the country is the third largest direct-selling market worldwide. Brazil also has a strong personal care market, with 20% of its personal care sales made through direct channels, according to Nu Skin

Latest Headlines
See All
UsernamePublicRestriction

Register

RS005848

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel